APP and LRP1B |
amyloid beta precursor protein |
LDL receptor related protein 1B |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
|
|
APP and MITF |
amyloid beta precursor protein |
melanocyte inducing transcription factor |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
- SUMOylation of transcription factors
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
|
- Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
- Waardenburg syndrome (WS)
- Malignant melanoma
|
APP and CCNG1 |
amyloid beta precursor protein |
cyclin G1 |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
- Regulation of TP53 Degradation
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
|
|
APP and TTLL7 |
amyloid beta precursor protein |
tubulin tyrosine ligase like 7 |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
- Carboxyterminal post-translational modifications of tubulin
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
|
|
APP and LINGO2 |
amyloid beta precursor protein |
leucine rich repeat and Ig domain containing 2 |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
|
|
APP and WWC3 |
amyloid beta precursor protein |
WWC family member 3 |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
|
|
APP and TGFB1 |
amyloid beta precursor protein |
transforming growth factor beta 1 |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
- Platelet degranulation
- Influenza Virus Induced Apoptosis
- Cell surface interactions at the vascular wall
- Molecules associated with elastic fibres
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Syndecan interactions
- ECM proteoglycans
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Transcriptional regulation of white adipocyte differentiation
- UCH proteinases
- Interleukin-4 and Interleukin-13 signaling
- RUNX3 regulates CDKN1A transcription
- Regulation of RUNX3 expression and activity
- RUNX3 regulates p14-ARF
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
- Hyaluronidase
- Hyaluronidase (Human Recombinant)
|
|
- Graft-versus-host disease
- Allograft rejection
- Camurati-Engelmann disease; Progressive diaphyseal dysplasia
|
FASLG and DLG2 |
Fas ligand |
discs large MAGUK scaffold protein 2 |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- Interleukin-4 and Interleukin-13 signaling
- Dimerization of procaspase-8
- FasL/ CD95L signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- FOXO-mediated transcription of cell death genes
- TNFs bind their physiological receptors
|
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Neurexins and neuroligins
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
|
|
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
|
FASLG and DMD |
Fas ligand |
dystrophin |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- Interleukin-4 and Interleukin-13 signaling
- Dimerization of procaspase-8
- FasL/ CD95L signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- FOXO-mediated transcription of cell death genes
- TNFs bind their physiological receptors
|
- Non-integrin membrane-ECM interactions
- Striated Muscle Contraction
|
|
|
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
- Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
- Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
- Dilated cardiomyopathy (DCM)
|
ARAF and BRAF |
A-Raf proto-oncogene, serine/threonine kinase |
B-Raf proto-oncogene, serine/threonine kinase |
- RAF activation
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
|
- Spry regulation of FGF signaling
- Frs2-mediated activation
- Frs2-mediated activation
- ARMS-mediated activation
- Signalling to p38 via RIT and RIN
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
|
|
- Sorafenib
- XL281
- N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
- N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide
- (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
- Vemurafenib
- Regorafenib
- Dabrafenib
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
- Thyroid cancer
- Malignant melanoma
|
AREG and MMP9 |
amphiregulin |
matrix metallopeptidase 9 |
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- COPII-mediated vesicle transport
- EGFR interacts with phospholipase C-gamma
- Constitutive Signaling by Aberrant PI3K in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- Cargo concentration in the ER
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Extra-nuclear estrogen signaling
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
RHOA and SPRED2 |
ras homolog family member A |
sprouty related EVH1 domain containing 2 |
- GPVI-mediated activation cascade
- Axonal growth inhibition (RHOA activation)
- Rho GTPase cycle
- PI3K/AKT activation
- Axonal growth stimulation
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- G beta:gamma signalling through PI3Kgamma
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- PCP/CE pathway
- G alpha (12/13) signalling events
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D induced cell migration and growth-cone collapse
- Sema4D induced cell migration and growth-cone collapse
- VEGFA-VEGFR2 Pathway
- RHO GTPases activate PKNs
- RHO GTPases activate CIT
- RHO GTPases activate CIT
- RHO GTPases activate KTN1
- RHO GTPases Activate ROCKs
- RHO GTPases Activate ROCKs
- RHO GTPases Activate Formins
- RHO GTPases Activate Rhotekin and Rhophilins
- RHO GTPases Activate Rhotekin and Rhophilins
- Ovarian tumor domain proteases
- ERBB2 Regulates Cell Motility
- Neutrophil degranulation
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- SLIT2:ROBO1 increases RHOA activity
|
- Regulation of RAS by GAPs
- FGFRL1 modulation of FGFR1 signaling
- RAS signaling downstream of NF1 loss-of-function variants
|
|
|
|
|
ARR3 and CLTC |
arrestin 3 |
clathrin heavy chain |
|
- Entry of Influenza Virion into Host Cell via Endocytosis
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
|
|
|
|
ARRB1 and CLTC |
arrestin beta 1 |
clathrin heavy chain |
- Activated NOTCH1 Transmits Signal to the Nucleus
- G alpha (s) signalling events
- Lysosome Vesicle Biogenesis
- Golgi Associated Vesicle Biogenesis
- Thrombin signalling through proteinase activated receptors (PARs)
- Activation of SMO
- Activation of SMO
- MAP2K and MAPK activation
- Ub-specific processing proteases
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Signaling downstream of RAS mutants
|
- Entry of Influenza Virion into Host Cell via Endocytosis
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
|
|
|
|
ARRB2 and CLTC |
arrestin beta 2 |
clathrin heavy chain |
- Activated NOTCH1 Transmits Signal to the Nucleus
- G alpha (s) signalling events
- Thrombin signalling through proteinase activated receptors (PARs)
- WNT5A-dependent internalization of FZD4
- Activation of SMO
- Activation of SMO
- MAP2K and MAPK activation
- Ub-specific processing proteases
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Signaling downstream of RAS mutants
|
- Entry of Influenza Virion into Host Cell via Endocytosis
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
|
|
|
|
ATP2B2 and DLG2 |
ATPase plasma membrane Ca2+ transporting 2 |
discs large MAGUK scaffold protein 2 |
- Reduction of cytosolic Ca++ levels
- Ion homeostasis
- Ion transport by P-type ATPases
|
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Neurexins and neuroligins
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
|
|
|
|
ATP2B4 and DLG2 |
ATPase plasma membrane Ca2+ transporting 4 |
discs large MAGUK scaffold protein 2 |
- Reduction of cytosolic Ca++ levels
- Ion homeostasis
- Ion transport by P-type ATPases
|
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Neurexins and neuroligins
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
|
|
|
|
BAD and BRAF |
BCL2 associated agonist of cell death |
B-Raf proto-oncogene, serine/threonine kinase |
- Activation of BAD and translocation to mitochondria
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- NRAGE signals death through JNK
- AKT phosphorylates targets in the cytosol
- Constitutive Signaling by AKT1 E17K in Cancer
|
- Spry regulation of FGF signaling
- Frs2-mediated activation
- Frs2-mediated activation
- ARMS-mediated activation
- Signalling to p38 via RIT and RIN
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
|
|
- Sorafenib
- XL281
- N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
- N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide
- (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
- Vemurafenib
- Regorafenib
- Dabrafenib
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
- Thyroid cancer
- Malignant melanoma
|
BARD1 and ACSL3 |
BRCA1 associated RING domain 1 |
acyl-CoA synthetase long chain family member 3 |
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
|
- Intracellular metabolism of fatty acids regulates insulin secretion
- Synthesis of very long-chain fatty acyl-CoAs
|
|
|
|
|
BGN and TGFB1 |
biglycan |
transforming growth factor beta 1 |
- A tetrasaccharide linker sequence is required for GAG synthesis
- Chondroitin sulfate biosynthesis
- Dermatan sulfate biosynthesis
- CS/DS degradation
- ECM proteoglycans
- ECM proteoglycans
- Defective B4GALT7 causes EDS, progeroid type
- Defective B3GAT3 causes JDSSDHD
- Defective CHST3 causes SEDCJD
- Defective CHST14 causes EDS, musculocontractural type
- Defective CHSY1 causes TPBS
- Defective B3GALT6 causes EDSP2 and SEMDJL1
|
- Platelet degranulation
- Influenza Virus Induced Apoptosis
- Cell surface interactions at the vascular wall
- Molecules associated with elastic fibres
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Syndecan interactions
- ECM proteoglycans
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Transcriptional regulation of white adipocyte differentiation
- UCH proteinases
- Interleukin-4 and Interleukin-13 signaling
- RUNX3 regulates CDKN1A transcription
- Regulation of RUNX3 expression and activity
- RUNX3 regulates p14-ARF
|
|
- Hyaluronidase
- Hyaluronidase (Human Recombinant)
|
|
- Graft-versus-host disease
- Allograft rejection
- Camurati-Engelmann disease; Progressive diaphyseal dysplasia
|